Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niacin/Laropiprant in Severe Dyslipoproteinemia
NCT01239992Phase 4Terminated
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Jun 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of niacin, laropiprant in hyperlipoproteinemia (HLP), metabolic syndrome, sponsored by Ludwig Maximilian University of Munich. Started Jun 2011; status: terminated.
02
Drugs
niacinlaropiprant
03
Conditions
hyperlipoproteinemia (HLP)metabolic syndrome
Beyond the preview
Go deeper on NCT01239992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01239992.